Pathos /
Rain
Pathos AI completes acquisition of Rain Oncology
What happened
Pathos AI, Inc. completed its acquisition of Rain Oncology Inc. on Jan. 26, 2024, after its wholly owned subsidiary WK Merger Sub, Inc. completed the tender offer.
Rain Oncology stockholders are to receive $1.16 per share in cash plus one contingent value right per share. Rain Oncology is a precision oncology company developing therapies.
The source
Everything on this page comes from the source below.
Pathos AI completes acquisition of Rain Oncology
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly